Long-term in vitro functional stability of compounded ranibizumab and aflibercept

Canadian Journal of Ophthalmology

Volumn 52, Issue 3, 2017, Pages 273-276

  Cao, Sijia ^a   Cui, Jing ^a   Matsubara, Joanne ^a   Forooghian, Farzin ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN RECEPTOR;

ARTICLE; DOSE RESPONSE; DRUG MANUFACTURE; DRUG STABILITY; DRUG STORAGE; ENZYME LINKED IMMUNOSORBENT ASSAY; IC50; IN VITRO STUDY; STORAGE TEMPERATURE; SYRINGE; CHEMISTRY; DRUG FORMULATION; DRUG PACKAGING; HUMAN;

ANGIOGENESIS INHIBITORS; DRUG COMPOUNDING; DRUG PACKAGING; DRUG STABILITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS;

EID: 85009481209     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.1016/j.jcjo.2016.11.012     Document Type: Article

References (17)

1. Khalili, H., Sharma, G., Froome, A., Khaw, P.T., Brocchini, S., Storage stability of bevacizumab in polycarbonate and polypropylene syringes. Eye (Lond) 29 (2015), 820–827.
2. Signorello, L., Pucciarelli, S., Bonacucina, G., et al. Quantification, microbial contamination, physico-chemical stability of repackaged bevacizumab stored under different conditions. Curr Pharm Biotechnol 15 (2014), 113–119.
3. Chen, Y.H., Wu, P.C., Shiea, J., Lo, L.H., Wu, Y.C., Kuo, H.K., Evaluation of the sterility, stability, and efficacy of bevacizumab stored in multiple-dose vials for 6 months. J Ocul Pharmacol Ther 25 (2009), 65–69.
4. Bakri, S.J., Snyder, M.R., Pulido, J.S., McCannel, C.A., Weiss, W.T., Singh, R.J., Six-month stability of bevacizumab (Avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing. Retina 26 (2006), 519–522.
5. Mansour, A.M., Al-Ghadban, S.I., Yunis, M.H., El-Sabban, M.E., Ziv-aflibercept in macular disease. Br J Ophthalmol 99 (2015), 1055–1059.
6. Shaikh, A.H., Toussaint, B.W., Miller, D.M., et al. Cost comparison of intravitreal aflibercept with bevacizumab and ranibizumab for the treatment of wet age-related macular degeneration. Ophthalmic Surg Lasers Imaging Retina 46 (2015), 62–66.
7. Elshout, M., van der Reis, M.I., Webers, C.A., Schouten, J.S., The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters. Graefes Arch Clin Exp Ophthalmol 252 (2014), 1911–1920.
8. Yannuzzi, N.A., Klufas, M.A., Quach, L., et al. Evaluation of compounded bevacizumab prepared for intravitreal injection. JAMA Ophthalmol 133 (2015), 32–39.
9. Kahook, M.Y., Liu, L., Ruzycki, P., et al. High-molecular-weight aggregates in repackaged bevacizumab. Retina 30 (2010), 887–892.
10. Palmer, J.M., Amoaku, W.M., Kamali, F., Quality of bevacizumab compounded for intravitreal administration. Eye (Lond) 27 (2013), 1090–1097.
11. Liu, L., Ammar, D.A., Ross, L.A., Mandava, N., Kahook, M.Y., Carpenter, J.F., Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling. Invest Ophthalmol Vis Sci 52 (2011), 1023–1034.
12. Matthews, J.L., Dubovy, S.R., Goldberg, R.A., Flynn, H.W. Jr, Histopathology of streptococcus mitis/oralis endophthalmitis after intravitreal injection with bevacizumab: a report of 7 patients. Ophthalmology 121 (2014), 702–708.
13. Sheyman, A.T., Cohen, B.Z., Friedman, A.H., Ackert, J.M., An outbreak of fungal endophthalmitis after intravitreal injection of compounded combined bevacizumab and triamcinolone. JAMA Ophthalmol 131 (2013), 864–869.
14. Goldberg, R.A., Flynn, H.W. Jr, Miller, D., Gonzalez, S., Isom, R.F., Streptococcus endophthalmitis outbreak after intravitreal injection of bevacizumab: one-year outcomes and investigative results. Ophthalmology 120 (2013), 1448–1453.
15. VanderBeek, B.L., Bonaffini, S.G., Ma, L., Association of compounded bevacizumab with postinjection endophthalmitis. JAMA Ophthalmol 133 (2015), 1159–1164.
16. Pilli, S., Kotsolis, A., Spaide, R.F., et al. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol 145 (2008), 879–882.
17. Moshfeghi, A.A., Rosenfeld, P.J., Flynn, H.W. Jr, et al. Endophthalmitis after intravitreal vascular [corrected] endothelial growth factor antagonists: a six-year experience at a university referral center. Retina 31 (2011), 662–668.